Invesco Ltd. Decreases Stock Holdings in Edwards Lifesciences Corporation $EW

Invesco Ltd. lessened its stake in Edwards Lifesciences Corporation (NYSE:EW) by 23.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,276,041 shares of the medical research company’s stock after selling 1,011,671 shares during the period. Invesco Ltd. owned 0.56% of Edwards Lifesciences worth $256,219,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $26,000. SouthState Corp purchased a new stake in Edwards Lifesciences during the first quarter valued at approximately $27,000. Rosenberg Matthew Hamilton purchased a new stake in Edwards Lifesciences during the second quarter valued at approximately $28,000. NewSquare Capital LLC boosted its stake in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares in the last quarter. Finally, Riverview Trust Co grew its holdings in Edwards Lifesciences by 44.5% in the second quarter. Riverview Trust Co now owns 516 shares of the medical research company’s stock worth $40,000 after purchasing an additional 159 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Up 0.6%

Shares of EW stock opened at $86.26 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The firm has a market capitalization of $50.05 billion, a PE ratio of 37.18, a P/E/G ratio of 3.82 and a beta of 0.97. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The stock’s 50-day simple moving average is $80.95 and its 200-day simple moving average is $78.74.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on EW shares. The Goldman Sachs Group set a $104.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Friday, October 31st. Stifel Nicolaus set a $100.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Friday. Robert W. Baird increased their price target on Edwards Lifesciences from $83.00 to $88.00 and gave the company a “neutral” rating in a research note on Friday. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target for the company in a report on Monday, November 3rd. Finally, Mizuho upped their price objective on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $92.91.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,314,725.84. The trade was a 24.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.